TEE
EIGR

Tibra Equities Europe’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Tibra Equities Europe’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,111
Closed -$466K – 466
2019
Q1 		$466K Buy
+1,111
New +$446K 0.05% 273

Other funds holding EIGR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Tibra Equities Europe's EIGR Position: Q2 2019 in Review

Tibra Equities Europe sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2019, closing a stake of 1,111 shares — an estimated $466K sold.

Tibra Equities Europe first reported a position in EIGR in Q1 2019 and held it in 1 quarter. The position peaked at $466K in Q1 2019. 78 funds tracked by Wall St. Rank hold EIGR as of Q2 2019.

  • Tibra Equities Europe reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 1,111 Eiger BioPharmaceuticals, Inc. shares in Q2 2019, an estimated $466K.
  • Tibra Equities Europe first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Eiger BioPharmaceuticals, Inc. position peaked at $466K in Q1 2019.
  • 78 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.